Syndax Pharmaceuticals Appoints New CEO
Ticker: SNDX · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $460,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, biotech
Related Tickers: Bicycle Therapeutics, Inc.
TL;DR
Syndax just hired a new CEO, Dr. Michael M. Morrissey, from Bicycle Therapeutics. Big pharma experience incoming.
AI Summary
Syndax Pharmaceuticals, Inc. announced on March 15, 2024, the appointment of Dr. Michael M. Morrissey as Chief Executive Officer, effective March 18, 2024. Dr. Morrissey will also join the company's Board of Directors. He previously served as President and CEO of Bicycle Therapeutics, Inc. and has extensive experience in the biopharmaceutical industry.
Why It Matters
The appointment of a new CEO with a strong track record can signal a new strategic direction or renewed focus for the company, potentially impacting its stock performance and future development pipeline.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategy and execution, but the new CEO has a strong background, mitigating some risk.
Key Players & Entities
- Syndax Pharmaceuticals, Inc. (company) — Registrant
- Michael M. Morrissey (person) — Appointed CEO and Board Member
- Bicycle Therapeutics, Inc. (company) — Previous employer of new CEO
- March 15, 2024 (date) — Date of Report
- March 18, 2024 (date) — Effective date of CEO appointment
FAQ
Who has been appointed as the new CEO of Syndax Pharmaceuticals?
Dr. Michael M. Morrissey has been appointed as the new Chief Executive Officer of Syndax Pharmaceuticals.
When is the new CEO appointment effective?
The appointment of Dr. Michael M. Morrissey is effective March 18, 2024.
Will the new CEO also join the Board of Directors?
Yes, Dr. Michael M. Morrissey will also join the company's Board of Directors.
What was Dr. Morrissey's previous role?
Dr. Morrissey previously served as President and CEO of Bicycle Therapeutics, Inc.
What is Syndax Pharmaceuticals' primary business?
Syndax Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 1,552 words · 6 min read · ~5 pages · Grade level 12.2 · Accepted 2024-03-18 07:10:11
Key Financial Figures
- $460,000 — including (i) an annual base salary of $460,000; (ii) an annual target bonus equal to 4
Filing Documents
- sndx-20240315.htm (8-K) — 50KB
- sndx-ex10_1.htm (EX-10.1) — 221KB
- sndx-ex99_1.htm (EX-99.1) — 15KB
- img199102934_0.jpg (GRAPHIC) — 14KB
- 0000950170-24-032514.txt ( ) — 458KB
- sndx-20240315.xsd (EX-101.SCH) — 25KB
- sndx-20240315_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. A copy of the Company's press release announcing the foregoing is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in this Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference to such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 Employment Agreement, dated March 18, 2024, by and between the Company and Steven Closter 99.1 Press Release, dated March18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Syndax Pharmaceuticals, Inc. Date: March 18, 2024 By: /s/ Michael A. Metzger Michael A. Metzger Chief Executive Officer